NO914839D0 - Merkete, modifiserte oligonukleotider - Google Patents

Merkete, modifiserte oligonukleotider

Info

Publication number
NO914839D0
NO914839D0 NO914839A NO914839A NO914839D0 NO 914839 D0 NO914839 D0 NO 914839D0 NO 914839 A NO914839 A NO 914839A NO 914839 A NO914839 A NO 914839A NO 914839 D0 NO914839 D0 NO 914839D0
Authority
NO
Norway
Prior art keywords
modified oligonucleotides
labeled
labelled
useful
therapy
Prior art date
Application number
NO914839A
Other languages
English (en)
Other versions
NO914839L (no
Inventor
Wilhelmus Henricus Ar Kuijpers
Franciscus Michael Kaspersen
Constant Adriaan Anton Boeckel
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NO914839D0 publication Critical patent/NO914839D0/no
Publication of NO914839L publication Critical patent/NO914839L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pinball Game Machines (AREA)
  • Medicinal Preparation (AREA)
NO91914839A 1990-12-10 1991-12-09 Merkete, modifiserte oligonukleotider NO914839L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9002714 1990-12-10

Publications (2)

Publication Number Publication Date
NO914839D0 true NO914839D0 (no) 1991-12-09
NO914839L NO914839L (no) 1992-06-11

Family

ID=19858122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914839A NO914839L (no) 1990-12-10 1991-12-09 Merkete, modifiserte oligonukleotider

Country Status (15)

Country Link
EP (1) EP0490434B1 (no)
JP (1) JP3143506B2 (no)
KR (1) KR920012106A (no)
AT (1) ATE190621T1 (no)
AU (1) AU646118B2 (no)
CA (1) CA2057292A1 (no)
DE (1) DE69132044T2 (no)
ES (1) ES2144992T3 (no)
FI (1) FI915780A (no)
HU (1) HUT63191A (no)
IE (1) IE914220A1 (no)
NO (1) NO914839L (no)
NZ (1) NZ240926A (no)
PT (1) PT99752B (no)
ZA (1) ZA919694B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
CA2150477A1 (en) * 1992-11-30 1994-06-09 Robert Allen Snow Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide
US5571680A (en) * 1994-01-21 1996-11-05 Beckman Instruments, Inc. Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis
IL114237A (en) * 1994-07-14 2000-08-31 Schering Ag Oligonucleotide conjugates and diagnostic processes utilizing the same
GB2291877B (en) * 1994-08-01 1998-09-23 Tom Robin Caine Boyde Interlinking at least two protein molecules via nucleic acid chains
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
KR20020082218A (ko) * 2000-01-28 2002-10-30 내셔날유니버서티오브싱가폴 신규 리간드 및 그것의 제조 방법
US20010051348A1 (en) 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
EP1283674A4 (en) * 2000-03-24 2005-04-27 Univ Temple THERAPY OF PROLIFERATIVE DISORDERS BY DIRECT IRRADIATION OF CELL CORE WITH TRITANTS FOR CORE-SPECIFIC ADMINISTRATION
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) * 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
WO1989005853A1 (en) * 1987-12-15 1989-06-29 Synthetic Genetics Nucleic acid chelate conjugate as therapeutic and diagnostic agents
WO1989006702A1 (en) * 1988-01-21 1989-07-27 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5109124A (en) * 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
ES2055907T3 (es) * 1989-03-07 1994-09-01 Genentech Inc Conjugados covalentes de lipidos y oligonucleotidos.
CA2049361A1 (en) * 1989-04-18 1990-10-19 Jack S. Cohen Oligodeoxynucleotides with 5'-linked chemical groups, method of product thereof and use thereof

Also Published As

Publication number Publication date
AU8896091A (en) 1992-06-11
PT99752A (pt) 1992-11-30
JP3143506B2 (ja) 2001-03-07
ATE190621T1 (de) 2000-04-15
HUT63191A (en) 1993-07-28
AU646118B2 (en) 1994-02-10
KR920012106A (ko) 1992-07-25
EP0490434B1 (en) 2000-03-15
ES2144992T3 (es) 2000-07-01
HU913867D0 (en) 1992-02-28
FI915780A (fi) 1992-06-11
PT99752B (pt) 1999-05-31
DE69132044T2 (de) 2000-09-28
DE69132044D1 (de) 2000-04-20
EP0490434A1 (en) 1992-06-17
FI915780A0 (fi) 1991-12-09
NZ240926A (en) 1993-11-25
JPH04290897A (ja) 1992-10-15
IE914220A1 (en) 1992-06-17
ZA919694B (en) 1992-10-28
NO914839L (no) 1992-06-11
CA2057292A1 (en) 1992-06-11

Similar Documents

Publication Publication Date Title
IS4408A (is) Telomerasi úr spendýrum
PT983087E (pt) Composicao de vacina multivalente com veiculo misto
IT1262896B (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
NO912585D0 (no) Oligonukleotid-analoger med terminal 3'-3'- henholdsvis 5'-5'-internukleotdisammenkobling.
DE69333107T2 (de) Dualer träger für immunogene konstrukte
NO20020348L (no) Peptid acceptor ligeringsmetoder
DK0733069T3 (da) Oprensede Primat CTLA-8-antigener og beslægtede reagenser
DE69132044D1 (de) Markierte, modifizierte Oligonokleotiden
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
FR2696744B1 (fr) Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
FR2707994B1 (fr) Composites moléculaires de siloxane, procédé de préparation desdits composites, et leurs utilisations.
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
NO20011817L (no) Ionebytte-tumormålsöking (IETT)
FR2714062B1 (fr) Promoteur modifié pour ARN polymérase, sa préparation et ses applications.
NO995858L (no) Ny klasse kationiske nukleinsyre-overføringsmidler
FR2789588B1 (fr) Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale
FI970299A (fi) Oligomeeriset kantajamolekyylit, joissa on määritetysti sisällytettyjä merkitsinryhmiä ja hapteeneja
FR2721314B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
IT1270817B (it) Coniugati di farmaci antivirali ad attivita' epatotropica, relativi veicolanti e composizioni farmaceutiche che li contengono